Look the FDA simply said "appears to be sufficient" for resubmission. There is no way that they could determine whether it is sufficient to grant approval or make a decision about an adult trial until after the submission has been examined. Posters here constantly overstate the position, but that's understandable given that SI does the same.
Look the FDA simply said "appears to be sufficient" for...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.0¢ |
Change
0.005(0.55%) |
Mkt cap ! $1.044B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 92.5¢ | 92.0¢ | $44.70K | 48.58K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 11317 | 92.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 56955 | 6 |
View Market Depth
| Last trade - 10.05am 11/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |